Artificial intelligence (AI) software developer CereHealth said that a brain imaging and analytics center operated by a CereScan subsidiary will be participating in a new phase II study evaluating a treatment for Parkinson's disease.
CereScan's facility in Littleton, CO, has been approved to serve as a qualified imaging facility for the phase II study sponsored by Sun Pharma Advanced Research Company to evaluate its K0706 drug in subjects with early Parkinson's disease. CereScan will serve as the SPECT imaging center for private clinical research site Denver Neurological Research, providing dopamine transporter (DaT) SPECT imaging to show the density of healthy dopamine neurons, according to the company.
